Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status

Journal of Clinical Investigation

Volumn 120, Issue 9, 2010, Pages 3296-3309

  Jiang, Zhe ^a   Deng, Tao ^a   Jones, Robert ^a   Li, Huiqin ^a   Herschkowitz, Jason I ^b,e   Liu, Jeff C ^a   Weigman, Victor J ^b   Tsao, Ming Sound ^c   Lane, Timothy F ^d   Perou, Charles M ^b   Zacksenhaus, Eldad ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PROTEIN; CRE RECOMBINASE; CYTOKERATIN; ESTROGEN RECEPTOR ALPHA; PROTEIN P107; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; WHEY ACIDIC PROTEIN;

ADENOSQUAMOUS CARCINOMA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST CELL; BREAST EPITHELIUM; BREAST HYPERPLASIA; BREAST TUMOR; CANCER INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOCAL ACINAR HYPERPLASIA; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; LACTATION DISORDER; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL METAPLASIA; STEM CELL; TUMOR CELL;

ANIMALS; CELL LINE; FEMALE; GENE DELETION; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956364828     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41490     Document Type: Article

References (83)

1. Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia. 1999;4(1):105-122.
2. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
3. Wood LD, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108-1113.
4. Chan TA, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008;5(5):e114.
5. Schneider BP, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010-8018.
6. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
7. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40(18):2667-2675.
8. Fan C, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355(6):560-569.
9. Herschkowitz JI, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76.
10. Hennessy BT, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116-4124.
11. Fulford LG, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22-34.
12. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108-118.
13. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006;12(11):537-544.
14. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial- mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989-997.
15. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117(2):273-280.
16. Foulkes WD, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482-1485.
17. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-5853.
18. Liu X, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007;104(29):12111-12116.
19. Saal LH, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet. 2008;40(1):102-107.
20. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science. 1988;241(4862):218-221.
21. T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YK. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science. 1988;242(4876):263-266.
22. Bookstein R, Lee EY, Peccei A, Lee WH. Human retinoblastoma gene: long-range mapping and analysis of its deletion in a breast cancer cell line. Mol Cell Biol. 1989;9(4):1628-1634.
23. Varley JM, Brammar WJ, Walker RA. Oncogene organisation and expression: prediction in breast cancer. Horm Res. 1989;32(suppl 1):250-253.
24. Varley JM, et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene. 1989;4(6):725-729.
25. Wang NP, To H, Lee WH, Lee EY. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene. 1993;8(2):279-288.
26. Trudel M, Mulligan L, Cavenee W, Margolese R, Cote J, Gariepy G. Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol. 1992;23(12):1388-1394.
27. Neve RM, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-527.
28. Gauthier ML, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell. 2007;12(5):479-491.
29. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res. 2008;10(5):R75.
30. Subhawong AP, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol. 2009;33(2):163-175.
31. Burkhart DL, Sage J. Cellular mechanisms of tumor suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671-682.
32. Bremner R, Zacksenhaus E. Cyclins, Cdks, E2f, Skp2, and more at the first international RB tumor suppressor meeting [published online ahead of print July 7, 2010]. Cancer Res. doi:10.1158/0008-5472.CAN-10-0358.
33. Nahle Z, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol. 2002;4(11):859-864.
34. Macleod KF, Hu Y, Jacks T. Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 1996;15(22):6178-6188.
35. Jiang Z, et al. E2F1 and p53 are dispensable whereas p21Waf1/Cip1 cooperates with Rb to restrict endoreduplication and apoptosis during skeletal myogenesis. Dev Biol. 2000;227(1):28-41.
36. Whyte P, et al. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature. 1988;334(6178):124-129.
37. Rb and a second cellular protein, p120. Cell. 1989;58(2):257-267.
38. Vooijs M, Berns A. Developmental defects and tumor predisposition in Rb mutant mice. Oncogene. 1999;18(38):5293-5303.
39. Robinson GW, Wagner KU, Hennighausen L. Functional mammary gland development and oncogene- induced tumor formation are not affected by the absence of the retinoblastoma gene. Oncogene. 2001;20(48):7115-7119.
40. Husler MR, Kotopoulis KA, Sundberg JP, Tennent BJ, Kunig SV, Knowles BB. Lactation-induced WAP-SV40 Tag transgene expression in C57BL/6J mice leads to mammary carcinoma. Transgenic Res. 1998;7(4):253-263.
41. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A. 1994;91(23):11236-11240.
42. Simin K, et al. pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. PLoS Biol. 2004;2(2):E22.
43. Wagner KU, Boulanger CA, Henry MD, Sgagias M, Hennighausen L, Smith GH. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development. 2002;129(6):1377-1386.
44. Li G, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 2002;129(17):4159-4170.
45. Vooijs M, te Riele H, van der Valk M, Berns A. Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells. Oncogene. 2002;21(30):4635-4645.
46. Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell. 2004;5(6):539-551.
47. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev. 2004;18(14):1681-1694.
48. Lee MH, et al. Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev. 1996;10(13):1621-1632.
49. LeCouter JE, et al. Strain-dependent myeloid hyperplasia, growth deficiency, and accelerated cell cycle in mice lacking the Rb-related p107 gene. Mol Cell Biol. 1998;18(12):7455-7465.
50. Jiang Z, Zacksenhaus E. Coordinated expression of Rb gene family in the mammary gland. Mech Dev. 2010;119(suppl 1):S39-S42.
51. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21(1):70-71.
52. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/ basal and non-epithelial cells. Breast Cancer Res. 2006;8(1):R7.
53. Shackleton M, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439(7072):84-88.
54. Stingl J, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439(7079):993-997.
55. Wagner KU, et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 1997;25(21):4323-4330.
56. Singh SK, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821-5828.
57. Ponti D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65(13):5506-5511.
58. Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E. Identification of tumorsphere- and tumor-initiating cells in HER2/neu-induced mammary tumors. Cancer Res. 2007;67(18):8671-8681.
59. Miyoshi K, et al. Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A. 2002;99(1):219-224.
60. Walker LC, Harris GC, Wells JE, Robinson BA, Morris CM. Association of chromosome band 8q22 copy number gain with high grade invasive breast carcinomas by assessment of core needle biopsies. Genes Chromosomes Cancer. 2008;47(5):405-417.
61. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-1428.
62. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD. EMT tumorigenesis in the mouse mammary gland. Lab Invest. 2007;87(12):1218-1226.
63. Muller PA, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009;139(7):1327-1341.
64. Aylon Y, Oren M. Living with p53, dying of p53. Cell. 2007;130(4):597-600.
65. TP53 mutation distribution. http://p53.free.fr/Database/p53-database- dist.html. Accessed July 19, 2010.
66. Walker DR, et al. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene. 1999;18(1):211-218.
67. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29(4):418-425.
68. Lin SC, et al. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004;64(10):3525-3532.
69. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077- 3080.
70. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837.
71. Chang MW, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267(5197):518-522.
72. Zhu L, et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. 1993;7(7A):1111-1125.
73. Muncaster MM, Cohen BL, Phillips RA, Gallie BL. Failure of RB1 to reverse the malignant phenotype of human tumor cell lines. Cancer Res. 1992;52(3):654-661.
74. Jiang Z, Zacksenhaus E. Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma. J Cell Biol. 2002;156(1):185-198.
75. Chew YP, Ellis M, Wilkie S, Mittnacht S. pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F. Oncogene. 1998;17(17):2177-2186.
76. Arima Y, et al. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res. 2008;68(13):5104-5112.
77. Smith GH, Medina D. Re-evaluation of mammary stem cell biology based on in vivo transplantation. Breast Cancer Res. 2008;10(1):203.
78. Matulka LA, Triplett AA, Wagner KU. Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev Biol. 2007;303(1):29-44.
79. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res. 2010;16(4):1094-1099.
80. Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res. 2008; 14(20):6376-6386.
81. Liu X, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007;104(29):12111-12116.
82. Ponzo MG, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 2009;106(31):12903-12908.
83. Rottenberg S, et al. High sensitivity of BRCA1-def icient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079-17084.